ClotCare: Treatment of Deep Vein Thrombosis (DVT)

ClotCare: Blood Clots, Stroke, Heart Attack

Thursday, November 21, 2024

Home | DVT/PE | Blood Clots | Coumadin/Warfarin | New Patients | Self Testing | Email List | Donate

Pick a Topic: Home New Postings Patient Postings Clinician Postings Join Our Email List Useful Web Links CE Opportunities Training Programs Guidelines DVT & PE Stories Editorial Board Financial Support About ClotCare DVT Coalition Contact Us Find info on a: Specific Medicine or Treatment Type of Medicine or Treatment Condition or Medical Procedure Lab Test Procedure Management Issue ClotCare complies with the HONcode standard for trustworthy health information: verify here. ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.	Treatment of Deep Vein Thrombosis Henry I. Bussey, Pharm.D. August 2004 Review: Bates SM, Ginsberg JS. Clinical Practice. Treatment of Deep-Vein Thrombosis. New England Journal of Medicine 2004; 351(3):268-277. This concise and authoritative review provides up to date information on risk factors for developing deep vein thrombosis (DVT), the basics of diagnosis, recommended initial anticoagulant treatment, the role of thrombolytic therapy, the controversy regarding the length and anticoagulation intensity of long-term therapy (or secondary prophylaxis), avoiding the post-thrombotic syndrome, and suggestions on which patients should be evaluated for a hypercoagulable state as well as the degree to which such conditions may increase the risk of recurrence. Clinicians in the U.S. may be less inclined to initiate a hypercoagulable workup than the Canadian authors of this paper suggest. In the U.S., the value of identifying a hypercoagulable condition in a given patient may have to be balanced against the fact that documenting such a condition may make it difficult for the patient to maintain and/or secure reasonable health insurance. Additionally, although the article examines the value of using the presence of hypercoagulable conditions and gender to estimate the risk of recurrence, it does not include recent limited data that suggest that elevated d-Dimer levels and persistence of ultrasound abnormalities also may help identify individuals who are at greater risk of DVT recurrence once anticoagulation is discontinued.	Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org. ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters. New Postings: Click here to view full list of new postings
ClotCare Home \| New Postings \| Patient Postings \| Clinician Postings \| Join Our Email List \| Useful Web Links CE Opportunities \| Training Programs \| DVT & PE Stories \| Editorial Board \| Financial Support About ClotCare \| DVT Coalition \| Donate to ClotCare \| Contact Us
Key topics discussed on ClotCare include: Blood Clots \| Deep Vein Thrombosis (DVT) \| Pulmonary Embolism (PE) \| Atrial Fibrillation (A. Fib or AF) \| Heart Attack \| Stroke \| Transient Ischemic Attack (TIA) \| Mini Stroke \| Bleeding Complications \| Vascular Surgery \| Surgical Blood Clot Removal \| Warfarin \| Coumadin \| Lovenox \| Low Molecular Weight Heparin (LMWH) \| Heparin \| Anticoagulants \| Plavix \| Aspirin \| Antiplatelets \| Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved. Terms, Conditions, & Privacy \| Image Copyright Information 19260 Stone Oak Parkway, Suite 101 \| San Antonio, TX 78258 \| 210-860-0487 Send comments to webmaster@clotcare.org. Thursday, November 21, 2024